Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 10 of 10 results for insulin degludec

  1. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 September 2013

  2. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 July 2015

  3. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

    NICE guideline
    Last updated
    17 August 2022
    View recommendations

    Sections for NG17

  4. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  5. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  6. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA924

  7. Collaboration between East Staffordshire CCG and Burton Hospitals NHS Foundation Provider Trust Pharmacy Team – Re-design of the management process to comply with NICE Technology Appraisals

    suppurtativa, Pbr included drugs inappropriately invoiced to the CCG e.g. insulin degludec, methotrexate. The enhanced engagement has...

    Shared learning
    Last updated
    30 April 2018

  8. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Evidence summary
    Published
    2 November 2012

  9. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Evidence summary
    Published
    2 November 2012

  10. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    10 September 2013